Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients with gastroenteropancreatic neuroendocrine tumors, a phase 3 trial found.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback